Abstracts tagged "Vasculitis"

Abstract Number: 1428 • ACR Convergence 2020
The Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Matthew J. Koster¹, Kenneth Warrington¹, Jian Han² and Shalini V. Mohan², ¹Mayo Clinic, Rochester, MN, ²Genentech, South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) has been proven to be safe and effective for the treatment of giant cell arteritis (GCA) in 2 randomized controlled trials; however,…
Abstract Number: 1919 • ACR Convergence 2020
Efficacy & Safety of Tocilizumab in Giant Cell Arteritis: A Single Centre NHS Experience Using Imaging (Ultrasound and PET CT) as a Diagnostic and Monitoring Tool
Alwin Sebastian¹, Abdul Kayani¹, Diana Prieto-Peña², Alessandro Tomelleri³, Madeline Whitlock¹, Kornelis S. M. van der Geest⁴ and Bhaskar Dasgupta¹, ¹Rheumatology, Mid and South Essex University Hospital NHS Foundation Trust, Southend University Hospital, United Kingdom, Westcliff on sea, England, United Kingdom, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, Netherlands, Groningen, Netherlands
Background/Purpose: Tocilizumab (TCZ), an IL-6 receptor blocker is approved to treat relapsing, refractory Giant cell arteritis (GCA) We here report our real-life clinical experience with…
Abstract Number: 2048 • ACR Convergence 2020
Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis
Valerie Benard¹, Cynthia Farhat², Melissa Zarandi-Nowroozi², Madeleine Durand³, Christian Pagnoux⁴, Pierre Charles⁵, Xavier Puechal⁶, Loïc Guillevin⁷ and Jean-Paul Makhzoum¹, ¹Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Internal Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada, ²Department of Medecine, University of Montreal, Montreal, QC, Canada, ³Department of Internal Medicine, Centre Hospitalier de l’Universite de Montreal (CHUM) and Centre de Recherche du Centre Hospitalier de l’Universite de Montreal (CRCHUM), Montreal, QC, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁷Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France
Background/Purpose: Organ or life-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two of the antineutrophil cytoplasm antibody-associated vasculitis (AAV), are treated with cyclophosphamide or…
Abstract Number: 0509 • ACR Convergence 2020
Classification of Patients with Relapsing Polychondritis Based on Somatic Mutations in UBA1
Marcela Ferrada¹, Keith Sikora², Sinisa Savic³, Yiming Luo⁴, Kristina Wells⁵, Emily Rose¹, Kaitlin Quinn⁶, Wendy Goodspeed¹, Anne Jones⁷, Mimi Le⁸, Amanda Ombrello⁹, Zuoming Deng¹⁰, Massimo Gadina¹¹, Wanxia Tsai¹², Ivona Aksentijevich⁷, Daniel Kastner¹³, David Beck¹⁴ and Peter C. Grayson¹⁵, ¹Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institutes of Health Clinical Center, Bethesda, MD, ³University of Leeds, England, United Kingdom, ⁴Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ⁵Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ⁶Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ⁷National Human Genome Research Institute, Bethesda, MD, ⁸Oregon Health & Science University, Portland, ⁹National Institutes of Health, Bethesda, ¹⁰National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, ¹¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ¹²National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, MD, ¹³National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ¹⁴National Human Genome Research Institute, Bethesda, ¹⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare, heterogenous, systemic inflammatory disease with a predilection for cartilaginous structures. Recently we discovered myeloid-restricted somatic mutations in UBA1 in…
Abstract Number: 1429 • ACR Convergence 2020
An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US
Kathryn Starzyk¹, Kimberly Milberg¹, Ashish Deshpande¹ and Gary Curhan¹, ¹OM1, Inc, Boston, MA
Background/Purpose: The mainstay of treatment for vasculitis has been corticosteroids and other cytotoxic and immunosuppressive medications (e.g., cyclophosphamide, methotrexate) to promptly achieve and maintain remission.…
Abstract Number: 1922 • ACR Convergence 2020
Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis
K. Bates Gribbons¹, Kaitlin Quinn², Mark Ahlman³, Peter Merkel⁴ and Peter C. Grayson⁵, ¹McGovern Medical School UT Houston, Houston, TX, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Positron emission tomography (PET) is useful to demonstrate fluorodeoxyglucose (FDG) uptake in the large arteries in both Takayasu’s arteritis (TAK) and giant cell arteritis…
Abstract Number: 2052 • ACR Convergence 2020
Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne² and Peter A. Merkel³, ¹University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ³Division of Rheumatology University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse…
Abstract Number: 051 • 2020 Pediatric Rheumatology Symposium
Pediatric Providers’ Perspectives on Suspected Immune-Mediated Diffuse Alveolar Hemorrhage and Clinical Care Pathways
Jessica Bloom¹ and Robert Fuhlbrigge ², ¹Children's Hospital Colorado, Aurora, Colorado, ²University of Colorado, Aurora
Background/Purpose: Immune-mediated diffuse alveolar hemorrhage (iDAH) is a life-threatening complication of pediatric rheumatologic diseases such as vasculitis, systemic lupus erythematosus, and antiphospholipid antibody syndrome. Delay…
Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium
Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus
Linda Wagner-Weiner ¹, Vidya Sivaraman ², Karen James ³, Eric Yen ⁴, Kathleen O'Neil ⁵, Dana Gerstbacher ⁶, Ann Marie Szymanski⁷, Kimberly Morishita ⁸ and David Cabral ⁹ for the CARRA investigators, ¹University of Chicago, Chicago, Illinois, ²Division of Rheumatology, Nationwide Children's Hospital, Bexley, ³University of Utah, 84113, Utah, ⁴UCLA, Los Angeles, California, ⁵University of Indiana School of Medicine, Indianapolis, Indiana, ⁶Stanford University School of Medicine, Palo Alto, California, ⁷Tampa, Florida, ⁸University of British Columbia - Vancouver, Vancouver, British Columbia, Canada, ⁹BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…
Abstract Number: 084 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease Shock Syndrome: A Single Center Cohort
Monica Bray¹, Jennifer Rammel ², Andrea Ramirez ³, Kristen Sexson ⁴, Fong Lam ⁵, Eyal Muscal ¹ and Marietta De Guzman ³, ¹Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ²Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, ⁵Section of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a well described vasculitis of childhood that is the leading cause of acquired heart disease in developed countries. Kawasaki disease…
Abstract Number: 102 • 2020 Pediatric Rheumatology Symposium
Implications of Positive Tests for ANCA in a Pediatric Population
Karen James¹, Peter Merkel ² and Aimee Hersh ³, ¹University of Utah, 84113, Utah, ²University of Pennsylvania, Philadelphia, ³University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Testing for ANCA, particularly performed by ELISA (anti-MPO/PR3) is highly sensitive and specific for ANCA-associated vasculitis (AAV). However ANCA testing may be used in…
Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Simone Melega ¹, Paul Brogan², Gavin Cleary ³, Aimee Hersh ⁴, Ozgur Kasapcopur ⁵, Satyapal Rangaraj ⁶, Rae Yeung ⁷, Andrew Zeft ⁸, Jennifer Cooper ⁹, Pooneh Pordeli ¹⁰, Petra Kirchner ¹¹ and Patricia Lehane ¹², ¹F. Hoffmann-La Roche, Ltd., Basel, Switzerland, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³Alder Hey Children's Hospital, Liverpool, United Kingdom, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, ⁶Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁷The Hospital for Sick Children, Toronto, Canada, ⁸The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, ⁹University of Colorado, Children's Hospital Colorado, Denver, ¹⁰F. Hoffmann-La Roche, Ltd., Mississauga, Canada, ¹¹F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
Abstract Number: 312 • 2019 ACR/ARP Annual Meeting
Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity
Arielle Mendel¹, Daniel Ennis ², Shirley Lake ³, Simon Carette ⁴ and Christian Pagnoux ⁴, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Sunnybrook Hospital, Toronto, ON, Canada, ⁴Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
Background/Purpose: High dose glucocorticoids (GC) are part of the initial treatment of ANCA-associated (AAV) and large vessel vasculitides (LVV). Prompt subsequent tapering limits toxicity. Adherence…
Abstract Number: 1679 • 2019 ACR/ARP Annual Meeting
Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Peter Merkel¹, Bernhard Hellmich ², David Jayne ³, Simon Rückinger ⁴, Zsuzsanna Tamas ⁵, Claus Thielert ⁵ and Othmar Zenker ⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁴Metronomia Clinical Research GmbH, Munich, Germany, ⁵InflaRx GmbH, Planegg, Germany, ⁶InflaRx GmbH, Jena, Germany
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases are both forms of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Standard of…
Abstract Number: 2627 • 2019 ACR/ARP Annual Meeting
Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis
Shinya Hirahara¹, Yasuhiro Katsumata ¹, Ken-ei Sada ², Hiroko Nagafuchi ³, Eiichi Tanaka ¹ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kitaku, Okayama, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan
Background/Purpose: Chronic inflammatory diseases such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) substantially affects patients’ daily lives, including their ability to work. Although the management…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].